RAD51 and cancer: The use of PARP enzyme inhibitors in cancer cells which are defective for BRCA1 and BRCA2, two proteins that localize the RAD51 recombinase to the sites of damaged DNA and promote HR repair, represent the best and most successful synthetic lethal approach in cancer therapy.